Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: Role of specific Akt isoforms

Endocrine-Related Cancer

Volumn 19, Issue 3, 2012, Pages 423-434

  Zitzmann, Kathrin ^a   Vlotides, George ^a   Brand, Stephan ^a   Lahm, Harald ^b,c   Spöttl, Gerald ^a   Göke, Burkhard ^a   Auernhammer, Christoph J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PERIFOSINE; PROTEIN AKT1; PROTEIN AKT3; PROTEIN KINASE B BETA; PROTEIN MDM2; S6 KINASE; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; BRONCHUS; CELL STRAIN; CELL STRAIN BON1; CELL STRAIN GOT1; CELL STRAIN NCI H727; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; NEUROENDOCRINE TUMOR; PANCREAS CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

APOPTOSIS; BRONCHIAL NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA FRAGMENTATION; HUMANS; INTESTINAL NEOPLASMS; NEOPLASM INVASIVENESS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PHOSPHORYLCHOLINE; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING;

EID: 84862700224     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0074     Document Type: Article

References (38)

1. Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, Wong S, Lu Y, Pins M, Dancey J et al. 2006 A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biology &Therapy 5 766-770. (doi:10.4161/cbt.5.7.2874)
2. Bendell JC, Nemunaitis J, Vukelja SJ, Hagenstad C, Campos LT, Hermann RC, Sportelli P, Gardner L & Richards DA 2011 Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 29 4394-4400. (doi:10.1200/JCO.2011.36.1980)
3. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC et al. 2008 Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. Journal of Clinical Investigation 118 3065-3074. (doi:10.1172/JCI34739)
4. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB III, Kaestner KH, Bartolomei MS, Shulman GI &Birnbaum MJ 2001a Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292 1728-1731. (doi:10.1126/science.292.5522.1728)
5. Cho H, Thorvaldsen JL, Chu Q, Feng F & Birnbaum MJ 2001b Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. Journal of Biological Chemistry 276 38349-38352. (doi:10.1074/jbc.C100462200)
6. Dillon RL, Marcotte R, Hennessy BT, Woodgett JR, Mills GB & Muller WJ 2009 Akt1 and Akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Research 69 5057-5064. (doi:10.1158/0008- 5472.CAN-08-4287)
7. Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, Lee VM, Szabolcs M, de Jong R, Oltersdorf T et al. 2005 Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Molecular and Cellular Biology 25 1869-1878. (doi:10.1128/MCB.25.5.1869-1878.2005)
8. Ernst DS, Eisenhauer E, Wainman N, Davis M, Lohmann R, Baetz T, Belanger K & Smylie M 2005 Phase II study of perifosine in previously untreated patients with metastatic melanoma. Investigational New Drugs 23 569-575. (doi:10.1007/s10637-005-1157-4)
9. Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X et al. 2010 Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clinical Cancer Research 16 1033-1041. (doi:10.1158/1078-0432.CCR-09-1837)
10. Gills JJ & Dennis PA 2009 Perifosine: update on a novel Akt inhibitor. Current Oncology Reports 11 102-110. (doi:10.1007/s11912-009-0016-4)
11. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG et al. 2006 Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107 4053-4062. (doi:10.1182/blood-2005-08-3434)
12. Hutchinson JN, Jin J, Cardiff RD, Woodgett JR & Muller WJ 2004 Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Research 64 3171-3178. (doi:10.1158/0008-5472.CAN-03-3465)
13. Kasajima A, Pavel M, Darb-Esfahani S, Noske A, Stenzinger A, Sasano H, Dietel M, Denkert C, Rocken C, Wiedenmann B et al. 2011 mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 18 181-192. (doi:10.1677/ERC-10-0126)
14. Koseoglu S, Lu Z, Kumar C, Kirschmeier P & Zou J 2007 AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines. Cancer Biology & Therapy 6 755-762. (doi:10.4161/cbt.6.5.3995)
15. Lee MW, Kim DS, Lee JH, Lee BS, Lee SH, Jung HL, Sung KW, Kim HT, Yoo KH & Koo HH 2011 Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration. Cancer Science 102 1822-1828. (doi:10.1111/j.1349-7006.2011.02025.x)
16. Luo J, Manning BD & Cantley LC 2003 Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4 257-262. (doi:10.1016/S1535-6108(03)00248-4)
17. Mendoza MC & Blenis J 2007 PHLPPing it off: phosphatases get in the Akt. Molecular Cell 25 798-800. (doi:10.1016/j.molcel.2007.03.007)
18. Momota H, Nerio E & Holland EC 2005 Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Research 65 7429-7435. (doi:10.1158/0008-5472.CAN-05-1042)
19. Mure H, Matsuzaki K, Kitazato KT, Mizobuchi Y, Kuwayama K, Kageji T & Nagahiro S 2010 Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro-Oncology 12 221-232. (doi:10.1093/neuonc/nop026)
20. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F &Riccardi C 1991 A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. Journal of Immunological Methods 139 271-279. (doi:10.1016/0022-1759(91)90198-O)
21. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL et al. 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research 66 1500-1508. (doi:10.1158/0008-5472.CAN-05-2925)
22. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM et al. 2011 Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associatedwith carcinoid syndrome(RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378 2005-2012. (doi:10.1016/S0140-6736(11)61742-X)
23. Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, Spiegel S & Grant S 2005 Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Research 65 2422-2432. (doi:10.1158/0008-5472.CAN-04-2440)
24. Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M et al. 2011 Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. Journal of Clinical Oncology 29 4243-4249. (doi:10.1200/JCO.2010.33.9788)
25. Saji M, Narahara K, McCarty SK, Vasko VV, La Perle KM, Porter K, Jarjoura D, Lu C, Cheng SY & Ringel MD 2011 Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene 30 4307-4315. (doi:10.1038/onc.2011.136)
26. Sawyers CL 2006 Will kinase inhibitors have a dark side? New England Journal of Medicine 355 313-315. (doi:10.1056/NEJMcibr062354)
27. Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon AP &Caplin ME 2006 Epidermal growth factor receptor expression and activation in neuroendocrine tumours. Journal of Neuroendocrinology 18 355-360. (doi:10.1111/j.1365-2826. 2006.01425.x)
28. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L &Robertson GP 2004 Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Research 64 7002-7010. (doi:10.1158/0008-5472.CAN-04-1399)
29. Stambolic V & Woodgett JR 2006 Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration. Trends in Cell Biology 16 461-466. (doi:10.1016/j.tcb.2006.07.001)
30. Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R &Modlin IM 2011 Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. Cancer 117 4141-4154. (doi:10.1002/cncr.26011)
31. Tschopp O, Yang ZZ, Brodbeck D, Dummler BA, Hemmings-Mieszczak M, Watanabe T, Michaelis T, Frahm J & Hemmings BA 2005 Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development 132 2943-2954. (doi:10.1242/dev.01864)
32. Vink SR, Lagerwerf S, Mesman E, Schellens JH, Begg AC, van Blitterswijk WJ & Verheij M 2006 Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. Clinical Cancer Research 12 1615-1622. (doi:10.1158/1078-0432.CCR-05-2033)
33. Vlotides G, Sorensen AS, Kopp F, Zitzmann K, Cengic N, Brand S, Zachoval R & Auernhammer CJ 2004 SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA. Biochemical and Biophysical Research Communications 320 1007-1014. (doi:10.1016/j.bbrc.2004.06. 051)
34. Wang L, Ignat A & Axiotis CA 2002 Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Applied Immunohistochemistry & Molecular Morphology 10 139-146. (doi:10.1097/00022744-200206000-00008)
35. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG et al. 2011 Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 364 514-523. (doi:10.1056/NEJMoa1009290)
36. Zhang B, Gu F, She C, Guo H, Li W, Niu R, Fu L, Zhang N &Ma Y 2009 Reduction of Akt2 inhibits migration and invasion of glioma cells. International Journal of Cancer 125 585-595. (doi:10.1002/ijc.24314)
37. Zitzmann K, Brand S, Baehs S, Goke B, Meinecke J, Spottl G, Meyer H & Auernhammer CJ 2006 Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochemical and Biophysical Research Communications 344 1334-1341. (doi:10.1016/j.bbrc.2006.04.043)
38. Zitzmann K, Ruden J, Brand S, Goke B, Lichtl J, Spottl G &Auernhammer CJ 2010 Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Letters 295 100-109. (doi:10.1016/j.canlet.2010.02.018)